Smell Outcome and Seropositivity Titre in Post-COVID-19 Patients.

ORL J Otorhinolaryngol Relat Spec

Department of Microbiology and Clinical Immunology, Faculty of Medicine, University Kebangsaan Malaysia, Kuala Lumpur, Malaysia.

Published: December 2023

AI Article Synopsis

  • The study aimed to assess olfactory function in patients during and after COVID-19 using a Malaysian version of the smell test and a questionnaire.
  • During the COVID-19 infection, a significant number of patients experienced reduced smell, but all regained normal olfactory function after recovery.
  • There was no link between smell test results and COVID-19 antibody levels, which remained stable for up to 12 months post-infection.

Article Abstract

Introduction: The aims of the study were to perform an olfactory assessment on patients active and post-COVID-19 using the culturally adapted Malaysian version Sniffin' Sticks identification smell test (mSS-SIT), to evaluate the patient olfactory outcome using a Malay short version of the Questionnaire of Olfactory Disorders-Negative Statements (msQOD-NS), as well as to evaluate seropositive titre (IgG) response using automated serology method.

Methods: Score for mSS-SIT was performed during the hospitalization, when patients had tested positive for SARS-CoV-2 (during COVID-19), and repeated after they had tested negative (after COVID-19). Also, each patient completed msQOD-NS and serology SARS-CoV-2 antibodies blood test was evaluated.

Results: During COVID-19, 2 of our patients were anosmia (6.5%), 22 (70.9%) were hyposmia, and 7 (22.6%) were normosmia. We repeated mSS-SIT on these same patients after COVID-19, and none of these subjects were hyposmia or anosmia, as they achieved a score >12. All our patients had scored 21 using msQOD-NS, meaning no impact on quality of life as they had regained their normal olfactory function. In this study also, we obtained no correlation between smell test and seropositivity titre COVID-19, and antibody levels gradually decreased over time till 6 months and remained stable up to 12 months.

Conclusion: From this study, we know full recovery of the sense of smell can be expected post-COVID-19 infection and COVID-19 antibody persists in the body up to 12 months of infection.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11251653PMC
http://dx.doi.org/10.1159/000531222DOI Listing

Publication Analysis

Top Keywords

seropositivity titre
8
smell test
8
covid-19 antibody
8
patients
6
covid-19
6
smell
4
smell outcome
4
outcome seropositivity
4
titre post-covid-19
4
post-covid-19 patients
4

Similar Publications

Background: The reproductive problem is an animal health-related bottleneck that constrains livestock genetic improvement efforts in tropical countries such as Ethiopia. The infectious causes of reproductive disorders are one cause of decreased reproductive efficiency. This study aimed to determine the seroprevalence to Bovine Herpesvirus-1 (BHV1), Bovine Viral Diarrhea Virus (BVDV), Neospora caninum (N.

View Article and Find Full Text PDF

Seroprevalence of Naegleria fowleri in the Houston-Galveston Texas Population.

Parasitol Res

December 2024

Department of Clinical Laboratory Sciences, School of Health Professions, Medical Branch, University of Texas, 301 University Blvd, Galveston, TX, 77555-0128, USA.

Naegleria fowleri is a free-living amoeba and the causative agent of Primary Amebic Meningoencephalitis (PAM), a rare yet almost always fatal disease that primarily affects children. While only 431 PAM cases have been reported worldwide, the southern states of the United States, including Texas, report the highest number of cases. Despite the high mortality of the disease, studies have identified antibodies to N.

View Article and Find Full Text PDF

Predicting the infecting dengue serotype from antibody titre data using machine learning.

PLoS Comput Biol

December 2024

MRC Centre for Global Infectious Disease Analysis and the Abdul Latif Jameel Institute for Disease and Emergency Analytics, School of Public Health, Imperial College London, London, United Kingdom.

The development of a safe and efficacious vaccine that provides immunity against all four dengue virus serotypes is a priority, and a significant challenge for vaccine development has been defining and measuring serotype-specific outcomes and correlates of protection. The plaque reduction neutralisation test (PRNT) is the gold standard assay for measuring serotype-specific antibodies, but this test cannot differentiate homotypic and heterotypic antibodies and characterising the infection history is challenging. To address this, we present an analysis of pre- and post-infection antibody titres measured using the PRNT, collected from a prospective cohort of Thai children.

View Article and Find Full Text PDF

Coinfection with human papillomavirus (HPV) and HIV compounds the risks of developing cervical, anal, and HPV-associated oral neoplasia. Safe prophylactic vaccines are available to prevent HPV infections in people with HIV(PWH). Yet, vaccine efficacy and duration of protection remain questionable.

View Article and Find Full Text PDF

Despite widespread adoption of "high-dose" glucocorticoid definitions across international immunisation guidelines (i.e., prednisone-equivalent dosing >20 mg/day, or >2 mg/kg/day in children), the rationale remains unclear.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!